D. Boral Capital Reaffirms “Buy” Rating for OS Therapies (NYSEAMERICAN:OSTX)

OS Therapies (NYSEAMERICAN:OSTX)‘s stock had its “buy” rating reiterated by research analysts at D. Boral Capital in a research note issued to investors on Monday,Benzinga reports. They currently have a $20.00 price objective on the stock.

A number of other analysts have also recently issued reports on OSTX. Zacks Research upgraded shares of OS Therapies from a “strong sell” rating to a “hold” rating in a research note on Tuesday, November 11th. Lake Street Capital cut their price target on shares of OS Therapies from $18.00 to $17.00 and set a “buy” rating on the stock in a report on Tuesday, November 18th. Three investment analysts have rated the stock with a Buy rating and one has issued a Hold rating to the stock. According to data from MarketBeat.com, the stock presently has an average rating of “Moderate Buy” and a consensus target price of $17.33.

OS Therapies Trading Down 3.0%

OSTX opened at $1.62 on Monday. The stock has a fifty day moving average price of $1.84 and a 200 day moving average price of $1.91. OS Therapies has a 1 year low of $1.12 and a 1 year high of $7.00. The stock has a market cap of $57.04 million, a price-to-earnings ratio of -1.98 and a beta of -4.02.

OS Therapies (NYSEAMERICAN:OSTX) last issued its earnings results on Friday, November 14th. The company reported ($0.21) earnings per share for the quarter. As a group, sell-side analysts forecast that OS Therapies will post -0.64 earnings per share for the current fiscal year.

Institutional Inflows and Outflows

Several institutional investors have recently bought and sold shares of the stock. Susquehanna International Group LLP acquired a new position in OS Therapies during the 3rd quarter worth $29,000. Mercer Global Advisors Inc. ADV acquired a new position in shares of OS Therapies during the third quarter valued at $40,000. Millennium Management LLC bought a new position in OS Therapies in the third quarter valued at about $183,000. Virtu Financial LLC increased its position in OS Therapies by 252.0% in the third quarter. Virtu Financial LLC now owns 75,801 shares of the company’s stock worth $149,000 after purchasing an additional 54,269 shares during the period. Finally, Two Sigma Investments LP bought a new stake in OS Therapies during the 3rd quarter worth about $169,000.

About OS Therapies

OS Therapies Incorporated, a clinical stage biopharmaceutical company, focuses on the identification, development, and commercialization of treatments for osteosarcoma and other solid tumors in the United States. Its pipeline includes OST-HER2, an off-the-shelf immunotherapy for osteosarcoma patients; and OST-tunable drug conjugate (OST-tADC), an antibody-drug conjugate technology, with a plug-and-play platform that features tunable pH sensitive silicone linkers.